Notice2026-19590
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production Activity; Merck, Sharp & Dohme LLC; (Drug Products and Intermediates); Rahway, New Jersey
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 24, 2026
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 184 (Thursday, September 24, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 184 (Thursday, September 24, 2026)]
[Notices]
[Pages 60578-60579]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-19590]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-119-2026]
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production
Activity; Merck, Sharp & Dohme LLC; (Drug Products and Intermediates);
Rahway, New Jersey
The Port Authority of New York and New Jersey, grantee of FTZ 49,
submitted a notification of proposed production activity to the FTZ
Board (the Board) on behalf of Merck, Sharp & Dohme LLC (Merck) for
Merck's facilities in Rahway, New Jersey within Subzone 49Y. The
notification conforming to the requirements of the Board's regulations
(15 CFR 400.22) was received on September 3, 2026.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished
product(s) and material(s)/component(s) would be added to the
production authority that the Board previously approved for the
operation, as reflected on the Board's website.
The proposed finished products include: immunological disorder drug
product; oncology spray dried intermediate; infectious disease spray
dry intermediate; deuterated neurologic disease drug product; metabolic
disorders drug product; metabolic disorders spray dry Intermediate; and
Neurologic Disease Spray Dry Intermediate which are duty free.
The proposed foreign-status materials/components include:
morpholine immunological disorder active pharmaceutical ingredient;
monoclonal antibody immunotherapy drug substance; pyrrolidine
cardiovascular active pharmaceutical ingredient; imidazole oncology
active pharmaceutical ingredient; alkaloid oncology active
pharmaceutical ingredient; pyrimidine oncology active pharmaceutical
ingredient; pyrimidine cardiovascular active pharmaceutical ingredient;
sulfonamide neurologic disease active pharmaceutical ingredient;
deuterated neurologic disease active pharmaceutical ingredient; furan
infectious disease active pharmaceutical ingredient;
[[Page 60579]]
oncology active pharmaceutical ingredient; peptide immunological
disorder active pharmaceutical ingredient; lactam oncology active
pharmaceutical ingredient; indole metabolic disorders active
pharmaceutical intermediate; peptide oncology active pharmaceutical
ingredient; and pyrimidine metabolic disorders active pharmaceutical
intermediate with duty rate ranges from duty-free to 6.5%.
The request indicates that certain materials/components are subject
to duties under section 232 of the Trade Expansion Act of 1962 or
section 301 of the Trade Act of 1974, depending on the country of
origin. The applicable section 232 and section 301 decisions require
subject merchandise to be admitted to FTZs in privileged foreign status
as described in 19 CFR 146.41.
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#1a7c6e605a6e687b7e7f347d756c"><span class="__cf_email__" data-cfemail="fc9a8886bc888e9d9899d29b938a">[email protected]</span></a>. The closing period for their receipt is November 3,
2026.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact John Frye at <a href="/cdn-cgi/l/email-protection#8ec4e1e6e0a0c8fcf7ebcefafcefeaeba0e9e1f8"><span class="__cf_email__" data-cfemail="72381d1a1c5c34000b173206001316175c151d04">[email protected]</span></a>.
Dated: September 21, 2026.
Colin Agostisi,
Executive Secretary.
[FR Doc. 2026-19590 Filed 9-23-26; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 24, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.